This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Journal ONCOLOGY Offers Two-Part "Primer" On Targeted Therapies In Solid Tumors

NORWALK, Conn., Nov. 16, 2012 /PRNewswire/ -- UBM Medica US announces that Cancer Network and the journal ONCOLOGY are presenting a two part primer report on targeted therapies in solid tumors. Targeted therapy has become both the centerpiece of the current era in cancer therapeutics and the foundation of the field's hope for future progress. Although the initial successes of targeted therapies occurred in hematologic malignancies, recent years have seen a string of promising results in a number of solid tumors.

In this two-part series in the UBM Medical journal ONCOLOGY, Dr. Franco Muggia and colleagues explore the progress that has been made in this area. Far more than just a compendium of trial results, these two articles address such fundamental questions as:

  • How "targeted" are the so-called "targeted drugs"?
  • In what way do targeted therapies constitute a meaningful improvement over chemotherapy?
  • How can emerging targeted agents be integrated with older therapies (both endocrine therapies and chemotherapies)?
  • What are the prospects for "targeted" immunotherapies?

In Part I, the authors discuss these and other questions with regard to targeted therapies for renal cell carcinoma, hepatocellular carcinoma, malignant melanoma, and gastrointestinal stromal tumors (and other sarcomas). In Part II, they focus on developments in breast cancer, lung cancer, malignant colorectal cancer, and certain gynecological cancers. 

Also of high interest are the commentaries by renowned experts that accompany both papers. Commentary authors for Part I include Dr. Richard Schilsky of the University of Chicago, who was recently named Chief Medical Officer of the American Society of Clinical Oncology, and Dr. John Marshall of Georgetown, a global leader in the development of new drugs for colon cancer and other GI cancers. 

Commenting on Part II are Dr. Craig Henderson, who has received numerous awards for his work in the field of breast cancer research, and Dr. John Hamm, medical director of the research program at the Norton Cancer Center.

About UBM Medica US

Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach—online, in print, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, online communities, drug databases, digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Websites include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, MusculoskeletalNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect – which provides marketing services across a number of communities, the largest of which are healthcare, medical device design and advanced manufacturing. UBM Connect also includes UBM Studios, the global leader in interactive digital environments. UBM Connect is a UBM plc company. For more information, visit http://www.UBMMedicaUS.com

Media contact: Jason J. GoldenContent Marketing Manager203-523-7040 jason.golden@ubm.com

SOURCE UBM Medica

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs